Investigator-Initiated Trials (IITs) represent a vital avenue for independent clinical research, enabling physicians and academic investigators to explore novel therapeutic hypotheses, expand indications for existing agents, and generate publishable evidence outside the constraints of industry-sponsored programs. At Protheragen, we empower investigators and institutions with comprehensive IIT protocol design and ethics review services, bridging the gap between scientific vision and regulatory-compliant clinical execution for radiopharmaceutical research programs.
An Investigator-Initiated Trial (IIT) is a clinical study conceived, designed, and conducted by an independent investigator or academic institution rather than a commercial sponsor. In the radiopharmaceutical domain, IITs serve a uniquely important function: they allow clinicians with deep domain expertise in nuclear medicine and oncology to investigate off-label applications of approved radioligands, evaluate novel radionuclide combinations, or pioneer theranostic strategies that may not align with a pharmaceutical company's immediate commercial priorities. The protocol design phase is the foundational step of any IIT, requiring meticulous attention to scientific rationale, study objectives, patient eligibility criteria, endpoint selection, statistical power calculations, and safety monitoring plans. For radiopharmaceutical IITs, this process is further complicated by the need to incorporate radiation dosimetry assessments, radionuclide handling procedures, and specialized imaging protocols that are not typically encountered in conventional drug trials.
Fig 1. Meta-research uncovered hurdles in placebo acquisition for IIT drug trials. (Speich, Benjamin, et al., 2021)
Ethics review is the gatekeeper of clinical research integrity. Before any IIT can commence, the protocol, informed consent forms, and all supporting documentation must receive approval from an Institutional Review Board (IRB) or Independent Ethics Committee (IEC). For radiopharmaceutical trials, the ethics review process demands heightened scrutiny due to the involvement of ionizing radiation, the potential for long-term radiotoxicity, and the specialized nature of informed consent required for participants exposed to radioactive compounds. Ethics committees evaluate whether the scientific rationale justifies the radiation exposure, whether the dose is as low as reasonably achievable (ALARA), whether vulnerable populations are adequately protected, and whether the informed consent process fully discloses radiation risks, pregnancy precautions, and long-term follow-up requirements.
Protheragen delivers a full-spectrum IIT protocol design and ethics review service tailored specifically for the radiopharmaceutical sector. From the earliest concept development through IRB/IEC submission and approval, our integrated team of clinical scientists, medical writers, regulatory specialists, and ethics advisors works alongside investigators to transform research hypotheses into GCP-compliant, regulator-ready clinical protocols.
Collaborative workshops to align study objectives with therapeutic rationale, define primary and secondary endpoints, and assess clinical feasibility. Input on biomarker strategies, patient selection criteria, and radiopharmaceutical-specific considerations including radionuclide choice and dosing rationale.
Drafting of ICH E6(R3) and ICH M11 CeSHarP-compliant clinical protocols incorporating radiation dosimetry plans, imaging schedules, and ALARA principles. Development of informed consent forms with specialized radiation risk disclosures and pregnancy precautions.
Guidance on regulatory pathway selection for IITs involving investigational radiopharmaceuticals. Preparation and submission of IND applications, Investigator Brochures, and regulatory correspondence with FDA, EMA, PMDA, and NMPA.
End-to-end preparation of ethics submission packages including protocol synopses, informed consent forms, investigator CVs, and safety documentation. Coordination of multi-site IRB submissions and management of committee feedback and amendments.
Incorporation of preclinical dosimetry data into protocol design to support dose selection and organ-at-risk assessment. Development of radiation safety protocols, personnel monitoring plans, and waste management procedures for clinical sites.
Evaluation of investigative site capabilities for radiopharmaceutical handling, imaging infrastructure, and patient recruitment potential. Identification of qualified principal investigators with nuclear medicine expertise and appropriate patient populations.
Sample size calculations powered for radiopharmaceutical efficacy endpoints. Design of case report forms (CRFs) capturing imaging data, dosimetry parameters, and safety outcomes. Statistical analysis plans aligned with regulatory expectations.
Development of safety monitoring plans including SAE reporting pathways, DSMB charters, and radiation-specific adverse event grading. Ongoing medical monitoring and expedited reporting to regulatory authorities and ethics committees.
Medical writing services for final study reports, manuscript preparation, and scientific presentation development. Ensuring data integrity and compliance with ICMJE authorship guidelines for investigator-led publications.
Protheragen distinguishes itself as a specialized radiopharmaceutical CRDMO and CRO partner, offering deep domain expertise that spans the entire development continuum from preclinical research through IIT clinical execution. Our investigator-centric approach ensures that scientific independence is preserved while operational excellence is delivered.
Ready to transform your radiopharmaceutical research concept into a regulator-approved clinical protocol? Contact us today to discuss your IIT protocol design and ethics review requirements. Our team of radiopharmaceutical clinical specialists is prepared to guide you from concept to committee approval with the scientific rigor and regulatory precision your program demands. Whether you are exploring a novel alpha-emitter therapy or expanding the therapeutic landscape of an established radioligand, Protheragen is your dedicated partner in advancing investigator-led innovation. Reach out to us now to schedule a consultation and take the first step toward bringing your radiopharmaceutical IIT to the clinic.
Reference